We are always on the look-out for developments that may advance the treatment options for mesothelioma patients.
In mid-August 2014 we found this news report, “CD157 important in malignant pleural mesothelioma”, from which we get this recent research information:
CD157 plays a pivotal role in the progression of malignant pleural mesothelioma (MPM) and may be useful in the stratification of patients into different prognostic groups, Italian research suggests.
CD157 is known to contribute to tumour progression in ovarian cancer by promoting mesenchymal differentiation, and parallels between ovarian and mesothelial cancer indicate that CD157 might also be involved in MPM, explain Ada Funaro (University of Torino) and colleagues.
To investigate this hypothesis, Funaro and team conducted in vitro and in vivo assays using human MPM cell lines and MPM surgical tissue samples….
“These data suggest that CD157 could be a promising candidate as a predictive marker of response to platinum-based therapy in biphasic MPM patients”, Funaro and co-authors conclude in Oncotarget.
We will monitor the medical literature for further advancements relevant to the care and possible cure of malignant mesothelioma.
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.